Literature DB >> 8302422

Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease).

T M Chan1, I K Cheng, K L Wong, K W Chan.   

Abstract

A novel renal complication was reported in a patient with angiofollicular lymph node hyperplasia (Castleman's Disease), who developed acute renal failure due to membranoproliferative glomerulonephritis. Renal biopsy showed marked mesangial hyperplasia, basement membrane thickening with subendothelial electron-dense deposits, interstitial plasma cell infiltration, and glomerular deposition of IgM and complement components. A resolution of systemic manifestations and an improvement in renal function followed prednisolone and azathioprine therapy. Disease relapse, with increasing proteinuria and the development of factor 8 inhibitor, occurred 3 months later. Sustained remission was achieved with prednisolone and cyclophosphamide therapy, which were given for 42 and 12 months, respectively. Renal biopsy during remission showed significant resolution of the mesangial hyperplasia and disappearance of interstitial plasmacytic infiltration as well as subendothelial electron-dense deposits.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8302422     DOI: 10.1159/000187576

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

Review 1.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

2.  Remission of secondary membranous nephropathy in a patient with Kimura disease after surgical resection.

Authors:  Sunhwa Lee; Yong Jin Yi; Hyung Ah Jo; Hyuk Huh; Kyung-Hwan Kim; Dong Ki Kim; Hajeong Lee
Journal:  Kidney Res Clin Pract       Date:  2014-08-23

3.  Unicentric Castleman's disease associated with end stage renal disease caused by amyloidosis.

Authors:  Eray Eroglu; Ismail Kocyigit; Aydin Unal; Murat Hayri Sipahioglu; Hulya Akgun; Leylagul Kaynar; Bulent Tokgoz; Oktay Oymak
Journal:  World J Clin Cases       Date:  2017-03-16       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.